Updates

** Divi's Laboratories DIVI.NS close up 4.8% at 6,580 rupees after drugmaker posts 23% jump in Q4 profit

** Stock top of Nifty pharma index .NIPHARM, which is up 0.5%

** At least four analysts raise PT on DIVI, lifting the median PT to 5,980 rupees, avg rating is "hold" -LSEG data

** Jefferies ("hold") says Divi's will be a key beneficiary of diversification out of China but sees some near-term earnings pain due to competition as drugmakers' patents expire

** DIVI's F12M PE is 63, highest on pharma index

** Nuvama ("buy") says premium valuation will sustain as Divi's custom synthesis business scales up with new products from large clients

** Stock up ~8% YTD, most on pharma index, which is down 7%

(Reporting by Nandan Mandayam and Hritam Mukherjee in Bengaluru)

((Hritam.Mukherjee@thomsonreuters.com;))